Home › Neuroblastoma › Maryland
Neuroblastoma clinical trials in Maryland
8 studies for Neuroblastoma are looking for participants at sites in Maryland.
Cities in Maryland
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- and 1 more
RecruitingPhase 3
Up to age 30 · All sexes · Updated Oct 2, 2026 · NCT06172296Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
4 Weeks · All sexes · Updated Oct 2, 2026 · NCT01109394Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 3 to 35 · All sexes · Updated Sep 24, 2026 · NCT06995872Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 4 and older · All sexes · Updated Sep 22, 2026 · NCT01005654Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 3
365 Days – 30 Years · All sexes · Updated Aug 25, 2026 · NCT03126916SPEARHEAD-3 Pediatric Study
- National Institutes of Health, Bethesda
RecruitingPhase 1/2
Ages 2 to 21 · All sexes · Updated Aug 11, 2026 · NCT05642455A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Jun 15, 2026 · NCT06041516Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RecruitingPhase 2
Ages 1 to 50 · All sexes · Updated Mar 13, 2026 · NCT01804634From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.